Source: International Congress 2015 – Lung function: effects on method, machine and disease on the measurement



Rating:

Share or cite this content

Citations should be made in the following way:
Patrick Jak (Amsterdam, Netherlands), Jerica Sinkeldam, Ivo Van der Lee, Herman Groepenhoff, Patrick Jak. Postural change in lung capillary blood volume is less in pulmonary hypertension (PH) compared to healthy controls. Eur Respir J 2015; 46: Suppl. 59, 303

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary Function and response to treatment in pulmonary arterial hypertension (PAH) Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Is the increase in NO lung transfer due to free plasmatic hemoglobin in pulmonary arterial hypertension? Source: International Congress 2015 – Pulmonary hypertension in lung disease Year: 2015 Cardiac function in idiopathic pulmonary arterial hypertension patients with a severely reduced diffusion capacity Source: International Congress 2015 – Pulmonary hypertension: the right ventricle and its load Year: 2015 Hemodynamic effects of different vasodilators in patients with type II pulmonary hypertension (PH) Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Reduced pulmonary capillary volume (Vc) is responsable for the increased alveolar exhaled nitric oxide (CANO) in patients with progressive systemic sclerosis (PSS) and pulmonary hypertension (PH) Source: Eur Respir J 2005; 26: Suppl. 49, 561s Year: 2005 Vasoreactivity to inhaled nitric oxide does not predict long term survival in pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension: the clinic I Year: 2016 Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT-1 study Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013 Clinical meaning of low DLCO in idiopathic pulmonary arterial hypertension (IPAH) - Prospective single centre study Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 The relationship of systolic pulmonary arterial pressure with pulmonary function test and the fractional exhaled nitric oxide level in Kyrgyz population. Source: International Congress 2019 – Imaging for prognostication and disease characterisation: 2019 update Year: 2019 Nitric oxide and oxygen inhalation during exercise in patients with chronic obstructive lung disease (COPD) and secondary pulmonary hypertension (PH) Source: Eur Respir J 2001; 18: Suppl. 33, 83s Year: 2001 Physical training and metabolics of nitric oxide in individuals with idiopathic pulmonary arterial hypertension. Source: International Congress 2019 – Exercise tolerance and its determinants across pathologies Year: 2019 Endothelial cell mechanics are altered in pulmonary arterial hypertension (PAH) Source: Annual Congress 2011 - Experimental pulmonary hypertension Year: 2011 Role of tadalafil in patients with hypoxia / lung disease induced (group 3) pulmonary hypertension Source: International Congress 2016 – Pulmonary hypertension: the clinic I Year: 2016 Small airways dysfunction in chronic thromboembolic pulmonary hypertension Source: International Congress 2015 – Dyspnoea and respiratory muscle mechanics dysfunction in disease Year: 2015 Analysis of pulmonary endothelial microparticles, haemodynamics and functional class in pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 Comparative analysis of estimated and measured maximal voluntary ventilation in patients with pulmonary hypertension Source: International Congress 2016 – Respiratory muscles and airways function: from physiology to clinical implications Year: 2016 Lung cGMP release subsequent to NO inhalation in pulmonary hypertension: responders versus nonresponders Source: Eur Respir J 2002; 19: 664-671 Year: 2002 Exhaled breath olfactory signature of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Pathways in pulmonary arterial hypertension: the future is here Source: Eur Respir Rev 2012 21: 321-327 Year: 2012 Pulmonary arterial hypertension (PAH) in patients with lung sarcoidosis (LS) Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis Year: 2008